BPC-157 Calculator
Also known as: Pentadeca Arginate (analogue)
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a sequence found in human gastric juice. Animal studies report effects on tendon, ligament, and gastrointestinal tissue repair, but no Phase 3 human trials have been completed. Typical research-protocol dosing is 200–500 µg one to three times daily, subcutaneous or intramuscular. At 5 mg / 2.5 mL (2 mg/mL concentration), a 250 µg dose draws to 12.5 units on a U-100 insulin syringe.
| 2 mg | lyophilized powder |
| 5 mg | lyophilized powder |
| 10 mg | lyophilized powder |
| 0.1 mg | ≈ 5 U-100 units (at 5mg / 2.5mL) |
| 0.2 mg | ≈ 10 U-100 units (at 5mg / 2.5mL) |
| 0.25 mg | ≈ 12.5 U-100 units (at 5mg / 2.5mL) |
| 0.3 mg | ≈ 15 U-100 units (at 5mg / 2.5mL) |
| 0.5 mg | ≈ 25 U-100 units (at 5mg / 2.5mL) |
How it's typically prepared
Reconstitute with bacteriostatic water and refrigerate. Most protocols dose by injection close to the site of injury (subcutaneous), though no human pharmacokinetic standard exists.
Frequently asked questions
- How many units is 250 mcg of BPC-157?
- On a U-100 insulin syringe, 250 µg (0.25 mg) of BPC-157 equals 12.5 units when reconstituted at 5 mg / 2.5 mL (2 mg/mL concentration).
- Is BPC-157 approved by the FDA?
- BPC-157 is not FDA-approved as a drug. Following the February 2026 HHS reclassification, it can be prescribed via licensed compounding pharmacies in the United States.
- What's the difference between BPC-157 and 'Pentadeca Arginate'?
- Pentadeca Arginate (PDA) is a closely related arginate-salt analogue marketed as more soluble and stable. Dose conversions vary by compounder.
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.